An integrated assessment of five phase II and III trials revealed high efficacy and tolerability of glecaprevir/pibrentasvir combination therapy for eight weeks or twelve weeks in individuals with hepatitis C virus infection with or without compensated cirrhosis, with most people attaining sustained virologic response at twelve weeks (SVR12). The safety profile was comparable to that noted in a pooled assessment of a global pan-genotypic population of people with hepatitis C virus infection who received glecaprevir/pibrentasvir.

Jeong Heo et al. undertook the study to examine safety and efficacy of glecaprevir/pibrentasvir  (pan-genotypic direct-acting antiviral combination therapy) for chronic hepatitis C virus infection. The study researchers evaluated pooled data on people having hepatitis C virus infection that were recruited in VOYAGE I and II, ENDURANCE 1 and 2, SURVEYOR II part 4 trials. These trials investigated the safety and efficacy of eight or twelve weeks of glecaprevir/pibrentasvir therapy.

Participants were either therapy-naïve or had received sofosbuvir or interferon-based therapy. Efficacy was assessed by determining the rate of SVR12 posttreatment. By monitoring noxious events and lab evaluations, determination of safety was done. A total of 265 participants were incorporated into the study. Notably, 179 (67.5%) participants were hepatitis C virus treatment-naïve, and the majority of the participants were either subgenotype 2A (44.5%) or 1B (48.7%). SVR12 was attained by 262 (98.9%) participants in the intention-to-treat population.

In total, 3 participants did not attain SVR12: 2 had non-virologic failures and 1 had virologic failure. The majority of the noxious events were grade 1/2; 8 participants (3.0%) had at least 1 grade ≥3 adverse events. There were no severe side effects associated with glecaprevir/pibrentasvir therapy, and grade ≥3 hepatic lab abnormalities were rare (0.8%).